(AOF) – Phaxiam Therapeutics (+32.26% to 4.10 euros) posts one of the strongest increases in the SRD market after announcing the launch of a new preclinical development program targeting a bacteria characterized by its strong resistance to antibiotics , Klebsiella pneumoniae. The ex-Erytech specifies that this bacteria “at the origin of numerous infections, in particular pneumonia, urinary infections, bacteremia” mainly infects immunocompromised people”, but that it has “expanded its potential targets to people who are not with no health problems.
“With the launch of this new program, Phaxiam Therapeutics is deploying its strategy in accordance with the plan presented at the time of the merger and reaffirming its positioning at the forefront of the fight against antibiotic resistance,” declares Thibaut du Fayet, Managing Director. “The K. pneumoniae bacteria represents a new target with a strong medical need, affecting a large population on a global scale, and for which antibiotics offer only a limited therapeutic solution.”
AOF – LEARN MORE
Learn more about the Pharmacy sector
Biotechs put to the test
These companies are suffering from a much less favorable economic cycle, which is reflected in particular by a drop in venture capital financing of start-ups. These companies are therefore obliged to carry out layoff plans. Added to this is a much more restrictive regulatory framework. First, in the United States, measures linked to the Inflation Reduction Act (IRA) could have a strong impact on the margins of stakeholders. Indeed, from 2026, the federal Medicare program will be able to renegotiate the price of drugs marketed for nine years (chemical) or 13 years (biological), with discounts that could range from 35 to 60% for biotechs. Likewise, in Europe, with the new drug regulations presented in Brussels in April, the duration of patent protection will be reduced if the innovative treatment is not marketed in all member countries within two years.